Patents Assigned to NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG
  • Methods for producing vaccine adjuvants
    Publication number: 20110162982
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.
    Type: Application
    Filed: December 3, 2010
    Publication date: July 7, 2011
    Applicant: Novartis Vaccines and Diagnostic, GmbH & Co. KG
    Inventors: Gottfried Kraus, Robert Eskes
  • Methods for producing vaccine adjuvants
    Publication number: 20110165192
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.
    Type: Application
    Filed: December 3, 2010
    Publication date: July 7, 2011
    Applicant: Novartis Vaccines and Diagnostics, GmbH & Co. KG
    Inventors: Harald Rueckl, Hanno Scheffczik, Barbara Santry
  • Methods for producing vaccine adjuvants
    Publication number: 20110165193
    Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane.
    Type: Application
    Filed: December 3, 2010
    Publication date: July 7, 2011
    Applicant: Novartis Vaccines and Diagnostics, GmbH & Co. KG
    Inventors: Harald Rueckl, Hanno Scheffczik
  • Influenza Vaccines Containing Hemagglutinin and Matrix Proteins
    Publication number: 20110027314
    Abstract: An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2 OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.
    Type: Application
    Filed: January 26, 2007
    Publication date: February 3, 2011
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG
    Inventors: Michael Broeker, Holger Kost
  • LOW-ADDITIVE INFLUENZA VACCINES
    Publication number: 20100183671
    Abstract: An influenza vaccine that lacks at least three of a mercurial preservative; an antibiotic; formaldehyde; and egg-derived materials. In some embodiments, the vaccine includes none of these four components.
    Type: Application
    Filed: June 27, 2008
    Publication date: July 22, 2010
    Applicant: Novartis Vaccines & Diagnostics GmbH & Co., KG
    Inventors: Jens-Peter Gregersen, Holger Luebben, Juergen Vorlop
  • CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA
    Publication number: 20090304729
    Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as ?-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.
    Type: Application
    Filed: November 1, 2006
    Publication date: December 10, 2009
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG
    Inventors: Jens-Peter Gregersen, Holger Kost
  • ANIMAL CELLS AND PROCESSES FOR THE REPLICATION OF INFLUENZA VIRUSES
    Publication number: 20080274141
    Abstract: Animal cells are described which can be infected by influenza viruses and which are adapted to growth in suspension in serum-free medium. Processes for the replication of influenza viruses in cell culture using these cells are furthermore described, as well as vaccines which contain the influenza viruses obtainable by the process or constituents thereof.
    Type: Application
    Filed: June 26, 2008
    Publication date: November 6, 2008
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG
    Inventors: Albrecht Groner, Jurgen Vorlop